Schaden oder Nutzen einer Therapie mit Erythropoietin?

Shasha D, George MJ, harrison LB (2003) Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98:1972–1079CrossRefGoogle Scholar

Boogerts M, Coiffier B, Kainz C and the Epoetin ß QOL Working Group (2003) Impact of epoetin ß on quality of life in patients with malignant disease. Brit J of Cancer 88:988–995CrossRefGoogle Scholar

Rizzo JD, Lichtin AE, Woolf SH et al. (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 19:4083–4107CrossRefGoogle Scholar

Bohlius J, Langensiepen S, Schwarzer G, Engert A on behalf of the Cochrane Hematological Malignancies Group (2003) Does erythropoietin improve overall survival of patients with malignancies? Final analysis of a comprehensive meta-analysis. Onkologie 26 (Sonderheft 5):25, V276Google Scholar

Stüben G, Pöttgen C, Knühmann K et al. (2003) Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiation Oncology Biol Phys 55:1358–1362CrossRefGoogle Scholar

Fyles AW, Milosevic M, Pintilie M et al. (2000) Anemia, hypoxia and transfusion in patients with cervix cancer : a review. Radiotherapy and Oncology 57:13–19CrossRefPubMedGoogle Scholar

Ludwig H, Fritz E. (2001) Overview of clinical trials on rHuEPO in cancer patients. In: Bokemeyer C, Ludwig H (eds) Anemia in Cancer. ESO Scientific Updates Vol. 6, pp 115–143Google Scholar

Littlewood TJ, Bajetta E, Nortier JWR et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874PubMedGoogle Scholar

Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460CrossRefPubMedGoogle Scholar

Blohmer JU, Wurschmidt F, Petry U et al. (2003) 6^th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-Intrgroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high risk cervical cancer. Proc Am Soc Clin Oncol 2003 #1798Google Scholar

Vansteenkiste J, Pirker R, Massuti B et al. (2002) Double-blind, placebo-controlled, randomized phase III trial of Darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220CrossRefPubMedGoogle Scholar